Finally, lab-quality

oral fluid rapid testS for THC and other drugs.

The world of drug testing is undergoing a major transformation, and nform is leading the charge. Urine tests are invasive, prone to adulteration and specimen substitution, and unsuitable for specifically detecting recent marijuana use. Back-to-lab tests can take 24-96 hours to deliver results, creating stress and uncertainty for individuals and organizations alike. Faster and more accurate alternatives are needed, and we are proud to offer the solution. The nform rapid oral fluid tests offer an observed specimen collection process, which can be administered by anyone, anywhere. In minutes, our tests deliver unmatched lab-like accuracy, meeting the strict SAMHSA laboratory screening standards for both sensitivity and specificity. With nform, we are revolutionizing drug testing as we know it.

Trust you’ve made the best decision when it matters most.

easy

User-friendly operation and results interpretation.

Rapid

Actionable results in minutes.

Accurate

The only rapid drug tests to meet the oral fluid screening standards set by SAMHSA and DOT.

Observed

Collected under direct observation, significantly reducing the risk of specimen tampering or substitution.

The only rapid-testing solutions you’ll ever need for virtually every need.

Marijuana Oral Fluid Rapid Test

THC cutoff of 4 ng/mL (aligns with the SAMHSA laboratory screening cutoff).
Proprietary ultra-sensitive chemistries give 10-fold greater sensitivity for THC detection when compared to current on-market visually-read rapid oral fluid tests.
Visually read with no instrumentation requirements.
Positive results in as little as 6 minutes.
Single specimen collection for both screening and confirmation of presumptive positives.
Oral Fluid collection pad material produced from untreated cotton, addressing potential religious and dietary concerns.
Unique formulation, minimizing specimen degradation during back-to-lab transportation for confirmation of presumptive positives.

view WORKFLOW

Employment Oral Fluid Panel

7 drug workplace panel with sensitivity that aligns with the SAMHSA laboratory screening cutoffs.
Amphetamine, Cocaine, Heroin (6-Acetyl Morphine), Methamphetamine, Opiates, Oxycodone and PCP.
Specificity of assays meet SAMHSA requirements of cross reactivity for Cocaine, Codeine, Hydrocodone, Hydromorphone, MDA, MDMA, and Oxymorphone.
Negative results in as little as 6 minutes.
Single specimen collection for both screening and confirmation of presumptive positives
Oral Fluid collection pad material produced from untreated cotton, addressing potential religious and dietary concerns.

VIEW DRUGS TESTED

Maintain personal and public safety while respecting individual privacy.

Employment

When job safety and productivity can’t wait, there’s nform. Now, anyone on-site can administer our non-invasive tests comfortably, and receive lab-quality results in under 15 minutes.

Public Safety

The road to healthier and safer communities starts now. Thanks to nform, our tests can easily be administered and read anywhere without the wait, improving safety on the roads and in society.

now you know now

Leading-edge technology from leading industry experts.

Michael Vincent, CEO

A diagnostics veteran with over 30 years of experience in toxicology, Michael's background spans entrepreneurship and senior corporate executive roles. During his ownership of Immunalysis and subsequent acquisition by Alere (NYSE:ALR), he steered the development of the world's largest opioid laboratory urine drug screening panel and advanced oral fluid specimens as an alternate biological matrix to urine in toxicology laboratory testing. His team obtained FDA clearance for 20 toxicology products, including 2 oral fluid collection devices. After Abbott’s (NYSE:ABT) acquisition of Alere in 2017, Michael headed R&D for the Toxicology Business Unit and was a member of the Abbott Scientific Governing Board.

Martin “Marty” Gould, CTO

With more than 40 years’ experience in the medical and diagnostic industries, Marty Gould has worked as a founder, senior manager, and business leader in six different diagnostic businesses. He has successfully been granted 10 patents, and is often referred to as one of the inventors of lateral flow immunoassay. As the CSO of ABMC, Marty developed the entire panel of drugs of abuse tests, established manufacturing operations, obtained ISO 13485 certification and successfully obtained multiple US FDA clearances for urine toxicology rapid tests. Two of the lateral flow businesses he founded, ADPI and Biosure Inc. were merged into CD Diagnostics and subsequently sold to Zimmer Biomet (NYSE: ZBH).

Christopher Tarpey, CCO

Chris Tarpey brings over 20 years’ experience in the in-vitro diagnostic field. From 2018 to 2022, Chris led Abbott Laboratories’ (NYSE: ABT) Toxicology Business Unit, heading a global team of 2,000 employees. From 2013-2018, Chris served as General Manager of eScreen, Inc., a leading third-party administrator of occupational health and drug screening programs in the United States. Chris was instrumental in evolving the eScreen diagnostic product portfolio, successfully positioning the organization’s electronic chain of custody form as first to market for regulated drug testing, and developing numerous strategic partnerships which further accelerated market penetration. Prior to joining eScreen, Chris served as Managing Director of Alere Toxicology plc, based in Oxfordshire, England, and held a variety of roles with Alere (NYSE: ALR), spanning sales, marketing, and business development.

About the company.

Founded in 2021, our mission is to accelerate innovation within the in-vitro diagnostic field, through the development of leading rapid diagnostic tests for the detection of drugs in oral fluid. nform’s proprietary technologies are highly differentiated, raising the bar for performance in rapid testing. We take pride in being the first to develop oral fluid rapid tests which meet the stringent Substance Abuse and Mental Health Services Administration (SAMHSA) laboratory drug screening standards for sensitivity and specificity.

We strive to empower organizations and individuals with accurate, actionable information at the point of collection, without the need to wait 24-96 hours for laboratory test results; thereby driving accelerated decision making, positive economic outcomes, and an optimized user experience.

The company maintains its research, development, and manufacturing operations in Newport, Delaware. Our products are developed and manufactured with pride in the USA.

faq.

What are the advantages of Oral Fluid Testing vs. Urine Drug Testing for THC?

THC (delta 9-tetrahydrocannabinol) is the primary psychoactive component in marijuana. THC can be detected in oral fluid immediately after marijuana use and is detectable for a matter of hours (at the SAMHSA screening cutoff of 4ng/mL). Oral fluid marijuana tests are designed to specifically test for this targeted chemical.

THC is metabolized by the body and converted into the non-psychoactive metabolite carboxy-THC (11-nor-9 carboxy-delta-9-tetrahydrocannabinol). Carboxy THC is eliminated from the body in urine, and can be detected in urine for weeks following marijuana use. Urine marijuana tests are specifically designed to detect this marijuana metabolite.

Oral fluid marijuana testing provides significant advantages by detecting only recent drug use, as compared to urine testing.

What are some of the advantages of Oral Fluid Testing?

Collected under direct observation, significantly reducing the risk of specimen tampering or substitution.
Commonly viewed as less intrusive and more hygienic when compared to urine testing, providing for an improved overall user experience.
Collected on location, reducing collection time and cost, and eliminating the need to maintain dedicated collection facilities.
Provides significant advantages in detecting recent drug use, making it uniquely suitable for reasonable suspicion and post-accident testing.

Are the detection rates for drugs in Oral Fluid lower than that of Urine?

As per data from the Quest Diagnostics Drug Testing Index the urine drug testing positivity rates for the General US Workforce (more than 6 million tests) was 5.6% in 2021. The oral fluid drug testing positivity rates for General US Workforce (almost 2 million tests) was 7.3%.

What differentiates the nform product line from other rapid oral fluid drug tests?

nform’s oral fluid rapid tests are the first to meet the SAMHSA Mandatory Guidelines for Federal Workplace Drug Testing screening cutoffs. Until now, these stringent drug screening cutoffs were only met by using laboratory drug tests.

nform THC is 10 times more sensitive than other on-market visual read oral fluid rapid tests, making it comparable to laboratory drug tests.

All tests on the nform 7 meet the cutoff requirements mandated by SAMHSA, including the requisite specificity to Cocaine, Codeine, Hydrocodone, Hydromorphone, MDA, MDMA and Oxymorphone.

How does the nform product line ensure adequate specimen volume for initial screening and laboratory confirmations?

nform’s untreated cotton collection pad, with a volume adequacy indicator, collects 1 mL of oral fluid (minimum recommended volume as per the SAMHSA guidelines) which is then added to 3 mL of nform’s stabilizing buffer in a collection tube. This ensures adequate specimen volume to perform the screening test and to perform laboratory confirmation for multiple drug classes without the need to collect a second specimen. The collection tube is processed in the laboratory without the need for special tools to break the test housing apart to access the specimen.

When will the nform product line be available?

Coming soon in 2024.

Get in touch.

Thank you! Your submission has been received.

Oops! Something went wrong while submitting the form.

Made with pride in the U.S.A.